FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304846> ?p ?o ?g. }

• W4367304846 abstract "<h3>Objective:</h3> To determine the significance of optic nerve (ON) T2-hyperintensity and optic atrophy on MRI. <h3>Background:</h3> The best imaging modality to investigate optic neuropathy etiologies is an orbital MRI. In acute optic neuritis, ON T2-hyperintensity and contrast enhancement (CE) are seen in 77% and 90% of patients, respectively. However, in chronic optic neuropathies, ON T2-hyperintensity and atrophy are typically seen. Interestingly, isolated ON T2-hyperintensity is often presumed to be due to optic neuritis, prompting unnecessary investigations and frequent referrals to neuro-ophthalmology. <h3>Design/Methods:</h3> Retrospective study of consecutive patients who underwent brain/orbit MRI with/without contrast at our institution between 07/01/2019–06/30/2022. Patients with ON T2-hyperintensity or atrophy were included. Medical records were reviewed to determine the etiology, if any, of the T2-hyperintensity and/or atrophy. <h3>Results:</h3> 491 patients were included (mean age 52±17 years; 57% men). 381/724 ONs had <b>T2-hyperintensity </b><b><i>without</i></b><b> atrophy</b>; diagnoses: inflammatory (100), compressive (94), glaucoma (19), multifactorial (47), other (69), unspecified (15), normal (37). 219/724 ONs had <b>T2-hyperintensity </b><b><i>and</i></b><b> atrophy</b>; diagnoses: inflammatory (36), compressive (50), glaucoma (30), multifactorial (39), other (36), unspecified (12), normal (16). 124/724 ONs had <b>atrophy </b><b><i>without</i></b><b> T2-hyperintensity</b>; diagnoses: inflammatory (13), compressive (12), glaucoma (32), multifactorial (21), other (24), unspecified (7), normal (15). 68/724 eyes with T2-hyperintensity or atrophy had a normal ophthalmologic examination. <h3>Conclusions:</h3> ON T2-hyperintensity on MRI is a non-specific finding; it can be seen in various acute and chronic optic neuropathies. ON T2-hyperintensity <b>with</b> ON atrophy <b>without</b> associated CE can occur secondary to chronic optic neuropathies, such as compressive and glaucomatous optic neuropathies, and is not highly associated with inflammatory optic neuropathies. Therefore, these radiological findings should not automatically prompt an urgent neuro-ophthalmology evaluation or further work-up for optic neuritis, such as a lumbar puncture. However, in the absence of a known cause of the optic neuropathy, an optic neuropathy work-up should be performed. <b>Disclosure:</b> Dr. Labella Alvarez has received research support from Fundación Alfonso Martín Escudero. Dr. Mosleh has nothing to disclose. Dr. Bouthour has nothing to disclose. Amit Saindane has nothing to disclose. Dr. Dattilo has nothing to disclose. Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurophoenix. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Newman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurodiem. The institution of Dr. Newman has received research support from GenSight. The institution of Dr. Newman has received research support from Chiesi/Santhera. The institution of Dr. Newman has received research support from NINDS/NIH. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Biousse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gensights Biologic. Dr. Biousse has received personal compensation in the range of $0-$499 for serving as a Consultant for Neurophoenix. The institution of Dr. Biousse has received research support from NIH. Dr. Biousse has received publishing royalties from a publication relating to health care. Dr. Biousse has received publishing royalties from a publication relating to health care." @default.
• W4367304846 created "2023-04-29" @default.
• W4367304846 creator A5031361641 @default.
• W4367304846 creator A5031795849 @default.
• W4367304846 creator A5042601080 @default.
• W4367304846 creator A5044809040 @default.
• W4367304846 creator A5047430867 @default.
• W4367304846 creator A5053230728 @default.
• W4367304846 creator A5064585664 @default.
• W4367304846 date "2023-04-25" @default.
• W4367304846 modified "2023-09-24" @default.
• W4367304846 title "Optic nerve T2-hyperintensity: a nonspecific marker of optic nerve damage (P2-9.004)" @default.
• W4367304846 doi "https://doi.org/10.1212/wnl.0000000000202628" @default.
• W4367304846 hasPublicationYear "2023" @default.
• W4367304846 type Work @default.
• W4367304846 citedByCount "0" @default.
• W4367304846 crossrefType "proceedings-article" @default.
• W4367304846 hasAuthorship W4367304846A5031361641 @default.
• W4367304846 hasAuthorship W4367304846A5031795849 @default.
• W4367304846 hasAuthorship W4367304846A5042601080 @default.
• W4367304846 hasAuthorship W4367304846A5044809040 @default.
• W4367304846 hasAuthorship W4367304846A5047430867 @default.
• W4367304846 hasAuthorship W4367304846A5053230728 @default.
• W4367304846 hasAuthorship W4367304846A5064585664 @default.
• W4367304846 hasConcept C118487528 @default.
• W4367304846 hasConcept C118552586 @default.
• W4367304846 hasConcept C126838900 @default.
• W4367304846 hasConcept C137627325 @default.
• W4367304846 hasConcept C142724271 @default.
• W4367304846 hasConcept C143409427 @default.
• W4367304846 hasConcept C146638467 @default.
• W4367304846 hasConcept C2776572573 @default.
• W4367304846 hasConcept C2780640218 @default.
• W4367304846 hasConcept C2780837183 @default.
• W4367304846 hasConcept C2781172350 @default.
• W4367304846 hasConcept C71924100 @default.
• W4367304846 hasConceptScore W4367304846C118487528 @default.
• W4367304846 hasConceptScore W4367304846C118552586 @default.
• W4367304846 hasConceptScore W4367304846C126838900 @default.
• W4367304846 hasConceptScore W4367304846C137627325 @default.
• W4367304846 hasConceptScore W4367304846C142724271 @default.
• W4367304846 hasConceptScore W4367304846C143409427 @default.
• W4367304846 hasConceptScore W4367304846C146638467 @default.
• W4367304846 hasConceptScore W4367304846C2776572573 @default.
• W4367304846 hasConceptScore W4367304846C2780640218 @default.
• W4367304846 hasConceptScore W4367304846C2780837183 @default.
• W4367304846 hasConceptScore W4367304846C2781172350 @default.
• W4367304846 hasConceptScore W4367304846C71924100 @default.
• W4367304846 hasLocation W43673048461 @default.
• W4367304846 hasOpenAccess W4367304846 @default.
• W4367304846 hasPrimaryLocation W43673048461 @default.
• W4367304846 hasRelatedWork W1999789662 @default.
• W4367304846 hasRelatedWork W2010911516 @default.
• W4367304846 hasRelatedWork W2029710456 @default.
• W4367304846 hasRelatedWork W2078979564 @default.
• W4367304846 hasRelatedWork W2094019218 @default.
• W4367304846 hasRelatedWork W2375078593 @default.
• W4367304846 hasRelatedWork W2749444725 @default.
• W4367304846 hasRelatedWork W2977915466 @default.
• W4367304846 hasRelatedWork W4313209101 @default.
• W4367304846 hasRelatedWork W2495313273 @default.
• W4367304846 isParatext "false" @default.
• W4367304846 isRetracted "false" @default.
• W4367304846 workType "article" @default.